Acetyl-L-Carnitine (ALCAR): A Comprehensive Reference
1. Identity and Chemical Characterization
Chemical Names and Nomenclature
Acetyl-L-carnitine (ALCAR or ALC), also known as levacecarnine, is an acetylated form of L-carnitine. It is an ester of the trimethylated amino acid, L-carnitine, and is synthesized in the human brain, liver, and kidney by the enzyme ALC-transferase. Its molecular formula is C₉H₁₇NO₄, and it carries the CAS registry number 3040-38-8. Acetylcarnitine is the most abundant naturally occurring carnitine derivative and is formed in a reaction in which the acetyl group displaces the hydrogen atom in the central hydroxyl group of carnitine.
Natural Sources and Endogenous Production
It is naturally produced by the human body and is available as a dietary supplement. In animals, biosynthesis of carnitine primarily occurs in the liver and kidneys; however, carnitine may also be absorbed in the diet, primarily from red meats, but also in significantly lower levels in many other foods such as nuts and seeds, legumes, vegetables, fruits, and cereals. Although carnitine naturally occurs in two stereoisomers, only the L-enantiomer is biologically active. Acetyl-L-carnitine and propionyl-L-carnitine are derivatives of L-carnitine that are naturally produced in the body; for example, during strenuous exercise, L-carnitine and acetyl-CoA are converted into acetyl-L-carnitine and CoA by carnitine acetyltransferase inside the mitochondria.
Common Pharmaceutical and Supplement Forms
As a commercial dietary supplement and pharmaceutical agent, ALCAR is available in several preparations:
- Oral tablets and capsules: The most common consumer form, with unit doses typically ranging from 250 mg to 1,000 mg.
- Oral liquid/solution: Used in some clinical trials and pharmaceutical formulations.
- Intravenous (IV) and intramuscular (IM) preparations: Acetyl-L-carnitine is given intravenously for alcohol withdrawal, nerve pain caused by antiviral drugs used to treat HIV, dementia, and reduced blood flow in the brain; it is also injected into the muscle for fibromyalgia and peripheral neuropathy.
- Hydrochloride salt form: Used in pharmaceutical-grade and clinical trial preparations (acetyllevocarnitine hydrochloride).
Both acetyl-L-carnitine and propionyl-L-carnitine are believed to have many advantageous properties over L-carnitine, such as increased bioavailability. Researchers prefer to use acetyl-L-carnitine to study the effects of carnitine in the body, because it has better absorption than L-carnitine in the small intestine and is more able to cross the blood–brain barrier.
2. Historical and Research Background
Discovery and Early Research
ALCAR is not an ingredient with a documented history of use in traditional herbal medicine systems. It is an endogenous mammalian biochemical identified in the context of modern scientific biochemistry. The therapeutic utilization of acetyl-L-carnitine has been progressively developed through pharmaceutical research; earlier therapeutic uses of acetyl-L-carnitine were identified through patent disclosures and clinical programs beginning in the late twentieth century. Early patents documented its use in the treatment of myocardial arrhythmias and ischemia, peripheral vascular diseases, and then impaired cerebral metabolism including senile and pre-senile dementia and Alzheimer's disease. U.S. Patent 4,346,107 disclosed the therapeutic effectiveness of acetyl carnitine in the treatment of patients suffering from impaired cerebral metabolism as it occurs in senile and pre-senile dementia and Alzheimer's disease. Subsequent patent literature extended these applications to peripheral neuropathies, coma, and fibromyalgia.
Because ALCAR is an endogenous molecule rather than a botanical or traditional herbal preparation, it has no documented history in classical Ayurvedic, Traditional Chinese Medicine, or European herbal systems. Its development has been driven entirely by biochemical and pharmacological research conducted from the mid-twentieth century onward.
3. Key Constituents and Active Compounds
ALCAR is itself the sole active compound of interest in supplemental form. Its biological activity derives from its chemical structure as an acetylated carnitine ester, which confers properties distinguishable from non-acetylated L-carnitine.
Relationship to L-Carnitine
Acetylcarnitine is broken down in the blood by plasma esterases to carnitine, which is used by the body to transport fatty acids into the mitochondria for breakdown and energy production. Carnitine is both a nutrient and made by the body as needed; it serves as a substrate for important reactions in which it accepts and gives up an acyl group. The body can convert L-carnitine to acetyl-L-carnitine and vice versa. However, no one knows whether the effects of acetyl-L-carnitine are from the chemical itself, from the L-carnitine it can make, or from some other chemical made along the way.
4. Mechanisms of Action
Mitochondrial Energy Metabolism
Acetyl-L-carnitine is synthesized in the human brain, liver, and kidney by the enzyme ALC-transferase. Acetyl-L-carnitine facilitates the uptake of acetyl CoA into the mitochondria during fatty acid oxidation, enhances acetylcholine production, and stimulates protein and membrane phospholipid synthesis. ALC facilitates the transport of fatty acids into mitochondria for β-oxidation, providing acetyl groups for energy production and maintaining acetyl-CoA levels, which is crucial for cellular metabolism and neurotransmitter synthesis.
Cholinergic Activity
ALC, similar in structure to acetylcholine, also exerts a cholinomimetic effect. Acetyl-L-carnitine is similar in form to the amino acid L-carnitine and also has some similar functions, such as being involved in the metabolism of food into energy. The acetyl group that is part of acetyl-L-carnitine contributes to the production of the neurotransmitter acetylcholine, which is required for mental function. Microdialysis studies have shown an increased acetylcholine release in both rat striatum and hippocampus following ALC administration.
Neurotrophic and Neuroprotective Effects
ALCAR has been found to have anti-inflammatory effects, lead to stabilization of membranes, act as an antioxidant protecting against oxidative stress, enhance the activity of nerve growth factor (NGF), and potentiate energy metabolism and cholinergic responses. This molecule is an acetyl-group donor and plays an important role in mitochondrial energy homeostasis and detoxification. Besides strengthening the actions of Nerve Growth Factor (NGF) and promoting peripheral nerve regeneration, ALC revealed a neuroprotective function in vitro, in vivo, and in animal models of diabetic neuropathy. ALC has antiapoptotic effects in peripheral mononeuropathy models, antioxidant activity, and accretes acetylcholine production.
Antioxidant Properties
ALC reduces oxidative stress by decreasing markers such as protein oxidation and lipid peroxidation, and increases antioxidant enzyme activity, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). The metabolic hypothesis is based on the oxidative metabolism of the acetyl component of acetyl-L-carnitine and is a simple explanation for the reduction in post-ischemic brain lactate levels and elevation of ATP seen with drug administration. The antioxidant mechanism is supported by reduction of oxidative stress markers, for example protein oxidation, in both brain tissue and cerebrospinal fluid.
Anti-inflammatory Activity
ALC suppresses inflammatory pathways, notably the TLR4/NF-κB axis, and downregulates pro-inflammatory cytokines such as TNF-α and IL-1β.
Epigenetic and Neurotransmitter Modulation
Acetyl-L-carnitine has antioxidant properties, protects from oxidative stress, modulates brain neurotransmitters such as acetylcholine, serotonin and dopamine, and acts on neurotrophic factors such as nerve growth factor (NGF) and metabotropic glutamate (mGlu) receptors by means of epigenetic mechanisms. Importantly, it induces mGlu2 expression at nerve terminals, thus giving rise to analgesia and preventing spinal sensitization. Since ALCAR is metabolized to acetyl CoA, it has the potential to acetylate histones, which can modify gene expression, and to acetylate proteins and enzymes, which can greatly modify activity.
Excitotoxicity Inhibition
The relatively uncharacterized mechanism of inhibiting excitotoxicity could be extremely important in both acute brain injury and chronic neurodegenerative disorders. New experiments performed with primary cultures of rat cortical neurons indicate that the presence of acetyl-L-carnitine significantly inhibits both acute and delayed cell death following exposure to NMDA, an excitotoxic glutamate antagonist.
5. Scientific Evidence by Area of Use
5.1 Cognitive Function, Dementia, and Alzheimer's Disease
This is one of the most extensively studied areas for ALCAR. Several studies explored the effects of acetyl-L-carnitine (ALC) in dementia, suggesting a role in slowing down cognitive decline. Several studies have reported that ALC treatment enhanced cognitive function or reduced the rate of cognitive deterioration in patients with Alzheimer's disease/mild cognitive impairment, Parkinson's disease, and hepatic encephalopathy.
The evidence base, while notable in volume, is qualified by important limitations. In 2003, a systematic review concluded there was insufficient evidence to recommend a clinical use, although a meta-analysis in the same year showed a significant advantage for ALC for clinical scales and psychometric tests. A 2003 Cochrane systematic review including 16 trials concluded that, even though some benefits of ALC were evident on the clinical global impression (CGI) and the Mini Mental State Examination (MMSE) at 24 weeks, there was little-to-no evidence when it came to employing objective assessments in other outcome measures.
A subsequent multicenter, randomized, double-blind, placebo-controlled trial examined ALC's effects in vascular cognitive impairment: the aim was to elucidate the efficacy of ALC in dementia patients with cerebrovascular disease. Fifty-six patients were randomized to treatment with 500 mg three times daily ALC, or placebo, in a 28-week trial. The primary outcome was measured by the Korean version of the Montreal Cognitive Assessment (MoCA-K). Following treatment with ALC, the cognitive function measured by the MoCA-K was significantly improved in the ALC-treated group. However, other secondary outcomes were not statistically significant. Attention and language sub-items significantly favored the ALC-treated group, and treatment with ALC 1,500 mg/day produced significant changes in MoCA-K.
Several studies explored the effects of acetyl-L-carnitine (ALC) in dementia, suggesting a role in slowing down cognitive decline. Nevertheless, in 2003 a systematic review concluded there was insufficient evidence to recommend a clinical use, although a meta-analysis in the same year showed a significant advantage for ALC for clinical scales and psychometric tests. Since then, other studies have been published; however, a critical review is still lacking. Further studies with homogeneous sample and longitudinal assessment are needed before a systematic clinical application.
Evidence strength: Moderate-weak. The available RCT data are mixed. Isolated trials report benefit, but the 2003 Cochrane review of 16 trials and subsequent analysis of larger studies found the clinical benefit was not substantial. The field requires better-powered and more methodologically uniform trials before firm conclusions can be drawn.
5.2 Peripheral Neuropathy (Diabetic and Other)
ALCAR has been studied with considerable rigor across multiple causes of peripheral neuropathy. The amino acid acetyl-L-carnitine (ALC) plays a role in the transfer of long-chain fatty acids into mitochondria for β-oxidation. ALC supplementation also induces neuroprotective and neurotrophic effects in the peripheral nervous system. Therefore, ALC supplementation targets several mechanisms relevant to potential nerve repair and regeneration, and could have clinical therapeutic potential.
A 2019 systematic review and meta-analysis identified four RCTs testing ALC in diabetic and antiretroviral-toxic neuropathy: in a double-blind RCT by De Grandis and colleagues involving 333 patients with diabetic neuropathy, mean nerve conduction velocity and amplitude significantly improved compared with placebo. Across four randomized controlled trials, compared to placebo, ALC produced a significant pain reduction equal to 20.2% (95% CI: 8.3%–32.1%, P<0.0001) with respect to baseline. Clinical trials also showed beneficial effects on nerve conduction parameters and nerve fiber regeneration, with a good safety profile. These data indicate that ALC provides an effective and safe treatment in patients with painful peripheral neuropathy.
A multicenter, randomized, double-blind, double-dummy, positive-controlled, non-inferior phase II clinical trial compared ALC to methylcobalamin: the trial was a multicenter, randomized, parallel-group, double-blind, double-dummy, positive-controlled, non-inferior study. Diabetic patients with abnormal nerve conduction test results were randomized in a 1:1 ratio to receive oral ALC 500 mg three times daily or methylcobalamin 0.5 mg three times daily for 24 weeks. The neuropathy symptom score, neuropathy disability score, and neurophysiological parameters were measured during follow-up. A total of 232 patients were randomized (ALC n=117, methylcobalamin n=115), and 88% completed the trial. A comparison of ALC versus methylcobalamin for the management of diabetic peripheral neuropathy found the efficacy of each to be similar, as demonstrated by statistically similar reductions in both the neuropathy symptom score and neuropathy disability score.
A Cochrane review on ALC for diabetic peripheral neuropathy applied a more conservative appraisal: the review concluded that it is very uncertain whether ALC causes a reduction in pain after 6 to 12 months' treatment in people with diabetic peripheral neuropathy, when compared with placebo, as the evidence is sparse and of low certainty. Data on functional and sensory impairment and symptoms are lacking, or of very low certainty.
An investigational multicenter double-blind placebo-controlled trial of 52 weeks in patients with type 2 diabetes and diabetic peripheral neuropathy tested doses of 0.5 grams or 1 gram three times daily, or placebo, for 52 weeks. Statistical analysis showed that treatment with ALC for 26 or 52 weeks was capable of treating and relieving the symptoms of diabetic peripheral neuropathy that were already present at the start of the clinical trial.
Evidence strength: Moderate. Multiple RCTs and a systematic review/meta-analysis support pain reduction and nerve conduction improvements in painful peripheral neuropathy of diabetic and HIV-related etiologies. However, a Cochrane review graded the overall certainty as low, citing sparse data and methodological heterogeneity. ALC is not listed as a first-line treatment in the American Academy of Neurology's evidence-based guidelines.
5.3 Chemotherapy-Induced Peripheral Neuropathy
Acetyl-L-carnitine (ALC), the acetyl ester of L-carnitine, plays an essential role in intermediary metabolism. Some of the properties exhibited by ALC include neuroprotective and neurotrophic actions, antioxidant activity, positive actions on mitochondrial metabolism, and stabilization of intracellular membranes.
A double-blind, placebo-controlled RCT totaling 239 patients with chemotherapy-induced peripheral neuropathy tested oral ALC: this study considered as primary endpoint the improvement of peripheral neuropathy by at least one grade according to the National Cancer Institute Common Toxicity Criteria version 3.0. Patients' conditions were assessed at weeks 4, 8, and 12 after enrollment. At week 8, 51.6% of patients treated with ALC met the primary endpoint, compared with 23.1% of patients in the placebo group. Secondary endpoints such as sural nerve conduction velocity and the Karnofsky physical score showed significant improvement in ALC-treated patients. No significant difference in the incidence of adverse events between the two groups was observed.
However, a critical safety signal has emerged specifically in the context of taxane chemotherapy: acetyl-L-carnitine might worsen symptoms in some people with nerve pain caused by a class of chemotherapy drugs known as taxanes. This finding is clinically significant and is reflected in oncology society guidelines.
Evidence strength: Conflicting. While one RCT using ALC 3 g/day showed benefit for chemotherapy-induced neuropathy, a prospective trial with taxane-based regimens found worsening of neuropathy, and the American Society of Clinical Oncology has recommended against its use for preventing chemotherapy-related nerve damage in taxane-treated patients. The evidence base is insufficient and contradictory for this indication.
5.4 Depression and Mood Disorders
Deficiency of acetyl-L-carnitine (ALC) appears to play a role in the risk of developing depression, indicating dysregulation of fatty acid transport across the inner membrane of mitochondria. However, the data regarding ALC supplementation in humans are limited; a systematic review and meta-analysis was conducted investigating the effect of ALC on depressive symptoms across randomized controlled trials.
A review published in 2014 summarized the clinical trial evidence: four randomized clinical studies (RCTs) demonstrated the superior efficacy of ALC over placebo in patients with depression. Two RCTs showed its superior efficacy over placebo in dysthymic disorder, and two other RCTs showed that it is equally effective as fluoxetine and amisulpride in treatment of dysthymic disorder. ALC was also effective in improving depressive symptoms in patients with fibromyalgia and minimal hepatic encephalopathy.
A metabolomic biomarker study observed that acetylcarnitine was significantly decreased in major depressive disorder and was distinguished from remission status, suggesting a potential biological relationship between ALCAR levels and depressive states.
The evidence base for depression focuses largely on geriatric populations and dysthymic disorder specifically. Most trials in this area are relatively small and older; larger, methodologically rigorous trials in broader depression populations are not yet available.
Evidence strength: Preliminary to moderate for late-life and dysthymic depression. The RCTs available show statistically significant benefits comparable to some antidepressants, but study populations were predominantly elderly, and the trials were small. Larger, better-powered trials are needed to confirm these findings in broader populations.
5.5 Male Infertility and Sperm Parameters
Carnitines are naturally occurring antioxidants in mammals and are normally abundant in the epididymal luminal fluid of men. Men with abnormal semen parameters have been reported to have significantly lower carnitine serum levels.
A systematic review and meta-analysis of three RCTs published by the NIH Office of Dietary Supplements found: a systematic review and meta-analysis of three randomized clinical trials examined the effects of 1 g/day to 3 g/day L-carnitine or acetyl-L-carnitine for 2 to 6 months on sperm parameters in 201 men aged 20 to 40 years who had infertility. Compared to placebo, supplemental carnitine improved sperm motility by 7.84% and morphology by 4.91% but did not affect sperm concentration. A 2022 Cochrane Review assessed the effectiveness of carnitine supplementation on male subfertility. The review included six randomized clinical trials in a total of 1,089 men with subfertility who took 1,000 to 3,000 mg/day carnitine for 8 weeks to 6 months.
Analysis shows that carnitines improve sperm swimming and production of normal-shaped sperm cells but do not affect sperm count or pregnancy rates, although there are only a few studies and scientific evidence is limited. Whilst it is possible that carnitines may benefit male infertility, more evidence is required regarding chances of pregnancy after carnitine therapy.
Evidence strength: Preliminary. Multiple RCTs and meta-analyses document improvements in sperm motility and morphology, but not sperm concentration, and evidence of improved pregnancy rates is insufficient. Studies used combinations of L-carnitine and acetyl-L-carnitine, making it difficult to attribute effects solely to ALCAR.
5.6 Hepatic Encephalopathy
The effects of ALC on the gut–liver–brain axis seem to identify the category of patients in which the new insights contribute most to the mechanisms of action of ALC, likely being the liver metabolism and the improvement of hepatic detoxifying mechanisms the primary targets. Clinical trials examining ALC in hepatic encephalopathy have reported improvements in cognitive function in this context, and ALC was also shown to be effective in improving depressive symptoms in patients with minimal hepatic encephalopathy. This area is considered a promising but still developing application of ALCAR, with further well-designed trials warranted.
Evidence strength: Preliminary. Current data are encouraging but limited to smaller trials; this area is not yet supported by major systematic reviews or guideline endorsements.
6. Body Systems and Health Areas Associated with ALCAR
- Central Nervous System: Cognitive function, memory, dementia, Alzheimer's disease, mild cognitive impairment, depression, mood disorders, hepatic encephalopathy
- Peripheral Nervous System: Diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, HIV antiretroviral-related neuropathy, nerve regeneration
- Metabolic/Mitochondrial: Fatty acid oxidation, energy metabolism, mitochondrial biogenesis, acetyl-CoA homeostasis
- Reproductive System: Male sperm motility, morphology, and fertility
- Antioxidant/Anti-inflammatory: Reduction of oxidative stress markers, anti-inflammatory cytokine modulation
- Hepatic System: Liver metabolism, hepatic encephalopathy, gut–liver–brain axis
Studies have shown that ALC may be of benefit in treating Alzheimer's dementia, depression in the elderly, HIV infection, diabetic neuropathies, ischemia and reperfusion of the brain, and cognitive impairment of alcoholism.
7. Dosage Forms and Dosages Reported in Studies
The following dosages reflect what has been specifically reported in published human clinical studies and trials. These are not recommendations.
- Most common dose in published research (general cognitive/neurological use): Most research involving acetyl-L-carnitine has used 500 mg three times per day, though some research has used double this amount.
- Chemotherapy-induced peripheral neuropathy (cisplatin): Acetyl-L-carnitine in the amount of 1,000 mg three times per day for eight weeks has been shown to improve nerve damage (neuropathy) caused by the chemotherapy drug cisplatin.
- Chemotherapy-induced peripheral neuropathy (general): A prospective, double-blind RCT totaling 239 patients with chemotherapy-induced peripheral neuropathy tested the effect of oral administration of ALC 3 g/day.
- Diabetic peripheral neuropathy (52-week trial): Patients were treated with acetyl-L-carnitine at a dose of 0.5 grams or 1 gram, three times daily, or with placebo for 52 weeks.
- Diabetic peripheral neuropathy versus methylcobalamin (24-week trial): Diabetic patients were randomized to receive oral ALC 500 mg three times daily or methylcobalamin 0.5 mg three times daily for 24 weeks.
- Vascular cognitive impairment (28-week trial): Fifty-six patients were randomized to treatment with 500 mg three times daily ALC or placebo in a 28-week, double-blind, placebo-controlled trial.
- Peripheral neuropathies (pharmaceutical patent range): From about 1,000 to about 2,000 mg of acetyl-L-carnitine or an equivalent amount of a pharmacologically acceptable salt thereof are administered daily via the oral or parenteral route. Generally, the treatment is continued for about 30–60 days.
- Male infertility meta-analysis: Three randomized clinical trials examined the effects of 1 g/day to 3 g/day L-carnitine or acetyl-L-carnitine for 2 to 6 months.
8. Safety, Adverse Effects, and Drug Interactions
General Tolerability
Acetyl-L-carnitine is generally considered safe for most adults and possibly safe for most children when taken by mouth. It can cause some side effects including stomach upset, nausea, vomiting, dry mouth, headache, and restlessness. It can also cause a "fishy" odor of the urine, breath, and sweat. Gastrointestinal effects — nausea, vomiting, abdominal cramps, and diarrhea — are the most common adverse effects, occurring primarily at doses exceeding 3 g/day. ALCAR may cause agitation in some users; mild restlessness and insomnia have been reported, particularly when taken later in the day.
Anticoagulant Interactions
There is a major interaction concern with acenocoumarol (Sintrom): acetyl-L-carnitine might increase the effectiveness of acenocoumarol, slowing blood clotting too much, which might increase the chance of bruising and bleeding. The dose of acenocoumarol might need to be changed. There is a moderate interaction concern with warfarin (Coumadin), and caution is warranted with this combination. ALCAR should be used with caution in people taking blood-thinning medication, as it can theoretically increase the anticoagulant effect, increasing the risk of bruising and bleeding. Regular INR monitoring is recommended when co-administered with warfarin.
Thyroid Hormone Interaction
ALCAR may decrease the effectiveness of thyroid hormone by interfering with its activity, potentially necessitating monitoring or dosage adjustments in patients on levothyroxine or similar therapies. People with an underactive thyroid (hypothyroidism) should not take ALC, as there is concern that it may interfere with the effectiveness of thyroid hormone replacement medications.
Antiepileptic Drug Interactions
Treatment with valproic acid, phenobarbital, phenytoin, and carbamazepine reduces blood levels of carnitine. This interaction is relevant to carnitine homeostasis in patients on these medications.
Seizure Risk
An increase in the number or seriousness of seizures has been reported in people with a history of seizures who have used L-carnitine by mouth or by IV. Since L-carnitine is related to acetyl-L-carnitine, there is a concern that this might also occur with acetyl-L-carnitine.
Taxane Chemotherapy Warning
Acetyl-L-carnitine might worsen symptoms in some people with nerve pain caused by a class of chemotherapy drugs known as taxanes. This safety signal emerged from a prospective clinical trial and represents a clinically important contraindication in oncology settings.
TMAO and Cardiovascular Considerations
Orally administered L-carnitine supplementation has been linked to an increase in trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), as unabsorbed carnitine is metabolized by the gut microbiota to TMA and later oxidized to TMAO in the liver. Elevated serum levels of TMAO have been linked by some studies to an increased risk of cardiovascular disease. The exact implications of these findings require more research.
Pregnancy and Lactation
Not enough is known about the use of acetyl-L-carnitine during pregnancy and breast-feeding to allow for a safety determination.
References
Volver